The healthcare landscape in Japan continues to confront challenges in containing the COVID-19 pandemic while attempting to accelerate vaccine rollouts. This has exacerbated fears over further delays to patients returning to hospitals and continued concern over hospital finances. Coupled with the government’s recent drug repricing, healthcare stakeholders are pushing for a reconsideration of the government’s cost containment efforts in the healthcare space. However, the Suga administration remains likely to continue pursuing policies to reduce overall public spending and patient costs, though it is becoming increasingly open to bolstering the environment for innovative pharma and digital health initiatives.

We see three trends emerging in the healthcare landscape in Japan that businesses should watch. Read the trends below for your business to include in your strategic planning:

Trend #1: First annual drug repricing had broad impact across therapy areas and product categories

Trend #2: Hospitals seek further relief from the MHLW ahead of next year’s medical fee revision

Trend #3: Key public sector stakeholders seek to revamp the country’s pharma strategy

Our Japan Healthcare Review helps healthcare companies stay ahead of evolving market access and reimbursement environments, enhancing your performance in Asia’s must-win markets. Get the full report for detailed analyses of these key trends, along with the impacts these trends have on your healthcare business.

Strategic planning season is ramping up and you need information about your markets, industry, and company in real-time to power your business decisions. Download our free mobile app to learn what is happening beyond market trends in must-win markets. Available on iOS and Android. To receive access to our full suite research, data, and events on your critical markets, start your free trial of FrontierView today.

Categories: